BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis

Completed

• Conditions: Autoimmune Encephalitis
• Interventions: Other: Retrospective evaluation of specific brain MRI features

• Registration Number: NCT05825690
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

The term "autoimmune encephalitis" denotes an heterogenous group of diseases commonly associated with autoantibodies targeting neural or glial antigens. Patients harboring antibodies against the leucine-rich glioma-inactivated protein 1 (LGI1) usually respond well to immunotherapy, but a significant percentage develop cognitive sequelae and disability nonetheless. These patients would likely benefit for more aggressive and prolonged immunotherapy, aiming to prevent permanent neurological deficits. Identifying features predicting poor outcome would be crucial to guide treatment decisions. Brain magnetic resonance imaging is a key diagnostic tool in the acute phase, but radiological changes may also appear in follow-up studies, including global brain atrophy, hippocampal atrophy and mesial temporal sclerosis. We hypothesize that specific changes identifiable in the acute and chronic phase underlie a higher risk of poor outcome and persistent neurological deficits.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-20
• Primary Completion: 2022-09-20
• Study Completion: 2022-12-20
• Study First Submitted: 2023-02-14
• Status Verified: 2023-04
• Study First Submitted QC: 2023-04-20
• Last Update Submitted: 2023-04-20
• Study First Posted: 2023-04-24
• Last Update Posted: 2023-04-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• • Patients with a definite diagnosis of LGI1-antibody-associated encephalitis
• available MRI records
• Ascertained positivity for LGI1-antibodies in serum and/or CSF

Exclusion Criteria

• • Positivity for another antibody against neural or glial antigens
• MRI images not available
• Not enough clinical data to ascertain outcome

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
LGI1- Patients	Retrospective evaluation of specific brain MRI features	Patients affected by autoimmune encephalitis with antibodies against LGI1

Primary Outcome Measures

Name	Time	Method
Cognitive dysfunction and disability	12 months	Main outcome measures will include cognitive dysfunction measured by appropriate neuropsychological evaluations, and psychiatric symptoms; it will be "none", "light", "moderate", "severe"

Trial Locations

Locations (1)

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes; 🇫🇷 Lyon, France